5 unchanged sentences
The Court has appointed a lead plaintiff, or the Lead Plaintiff.
−Removed: O n January 13, 2026, Lead Plaintiff filed an amended complaint.
+Added: On January 13, 2026, Lead Plaintiff filed an amended complaint.
+Added: Following the second CRL issued by the FDA on April 10, 2026 for the Company's RP1 BLA for the treatment of advanced melanoma, the Lead Plaintiff filed a second amended complaint in the class action that addresses the second CRL.
+Added: The Company’s and the other defendants’ response is now due August 17, 2026.
The Company and the other defendants deny any wrongdoing and will vigorously defend this action.
Following the class action complaint, three shareholders filed separate derivative actions on behalf of the Company in the District of Massachusetts captioned Chea v.
+Added: Patel et al., Case No.
1:25-cv-12316-JEK, Wright v.
+Added: Patel et al., Case No.
1:25-cv-12401-WGY, and Vochten v.
+Added: Patel et al., Case No.
1:25-cv-12484-JEK.
4 unchanged sentences
The board of directors determined to defer action on the demand pending further developments in the class action.
−Removed: On September 29, 2025, the U.S.
−Removed: Securities and Exchange Commission, or the SEC, informed the Company that it is conducting an investigation and requested that the Company produce certain documents and communications connected with the RP1 BLA.
+Added: On September 29, 2025, the SEC, informed the Company that it was conducting an investigation and requested that the Company produce certain documents and communications connected with the RP1 BLA.
The investigation is reviewing essentially the same subject matter raised in the litigation following the CRL.
−Removed: The Company is cooperating with the SEC’s investigation and providing the requested materials.
+Added: On June 24, 2026, the SEC informed the Company that it has concluded its investigation of the Company and that it is not recommending an enforcement action be taken against the Company.
+Added: On August 6, 2026, a class action complaint alleging violations of the federal securities laws was filed against the Company and its directors and certain officers in the District of Massachusetts.
+Added: The complaint, captioned Toor v.
+Added: Replimune Group, Inc.
+Added: et al., Case No.
+Added: 1:26-cv-13612, alleges essentially the same facts and circumstances as the Lead Plaintiff's case.
+Added: The Company and the other defendants deny any wrongdoing and continue to vigorously defend this action.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.